Next Article in Journal
Impact of Mixed Equine Influenza Vaccination on Correlate of Protection in Horses
Next Article in Special Issue
Fast Tracks and Roadblocks for Zika Vaccines
Previous Article in Journal
Exosomes, Their Biogenesis and Role in Inter-Cellular Communication, Tumor Microenvironment and Cancer Immunotherapy
Previous Article in Special Issue
Zika Virus Vaccines: Challenges and Perspectives
Article Menu

Export Article

Open AccessReview
Vaccines 2018, 6(4), 70;

Assay Challenges for Emerging Infectious Diseases: The Zika Experience

GeneOne Life Science, Inc., Seoul 60606, Korea
Author to whom correspondence should be addressed.
Received: 12 September 2018 / Revised: 24 September 2018 / Accepted: 26 September 2018 / Published: 2 October 2018
(This article belongs to the Special Issue Development of Vaccines against Zika Virus)
Full-Text   |   PDF [246 KB, uploaded 2 October 2018]


From the perspective of vaccine development, it is imperative to accurately diagnose target infections in order to exclude subjects with prior exposure from evaluations of vaccine effectiveness, to track incident infection during the course of a clinical trial and to differentiate immune reactions due to natural infections from responses that are vaccine related. When vaccine development is accelerated to a rapid pace in response to emerging infectious disease threats, the challenges to develop such diagnostic tools is even greater. This was observed through the recent expansion of Zika virus infections into the Western Hemisphere in 2014–2017. When initial Zika vaccine clinical trials were being designed and launched in response to the outbreak, there were no standardized sets of viral and immunological assays, and no approved diagnostic tests for Zika virus infection. The diagnosis of Zika virus infection is still an area of active research and development on many fronts. Here we review emerging infectious disease vaccine clinical assay development and trial execution with a special focus on the state of Zika virus clinical assays and diagnostics. View Full-Text
Keywords: emerging infectious disease; vaccines; immune response; virus detection; zika virus; flaviviruses; clinical trials emerging infectious disease; vaccines; immune response; virus detection; zika virus; flaviviruses; clinical trials
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Roberts, C.C.; Maslow, J.N. Assay Challenges for Emerging Infectious Diseases: The Zika Experience. Vaccines 2018, 6, 70.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Vaccines EISSN 2076-393X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top